Filing Details

Accession Number:
0001209191-21-058424
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-10-01 16:08:42
Reporting Period:
2021-09-30
Accepted Time:
2021-10-01 16:08:42
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1492426 Horizon Therapeutics Public Ltd Co HZNP () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1349376 P Timothy Walbert C/O Horizon Therapeutics Plc
Connaught House, 1St Fl, 1 Burlington Rd
Dublin L2 4
Chairman, President And Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Disposition 2021-09-17 107,739 $0.00 739,984 No 5 G Direct
Ordinary Shares Acquisiton 2021-09-17 107,739 $0.00 107,739 No 5 G Indirect See footnote
Ordinary Shares Disposition 2021-09-17 110,502 $0.00 629,482 No 5 G Direct
Ordinary Shares Acquisiton 2021-09-17 110,502 $0.00 131,496 No 5 G Indirect By Spouse
Ordinary Shares Disposition 2021-09-30 30,460 $109.96 599,022 No 4 S Direct
Ordinary Shares Disposition 2021-09-30 18,940 $110.80 580,082 No 4 S Direct
Ordinary Shares Disposition 2021-09-30 600 $112.01 579,482 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 5 G Direct
No 5 G Indirect See footnote
No 5 G Direct
No 5 G Indirect By Spouse
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. The shares are held by the Timothy P. Walbert Gift Trust, of which the Reporting Person's spouse is the Trustee and beneficiary.
  2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2021.
  3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.48 to $110.47 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.48 to $111.37 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.73 to $112.12 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.